Cohort Studymoderate evidence
Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study.
The Lancet. Neurology·September 24, 2026·PMID 42785333
Why it mattersPlasma biomarkers may offer a practical way to monitor biological response to anti-amyloid therapy, but their trajectories are complex and not uniformly normalising. Understanding which markers reflect amyloid clearance versus immune or neurodegenerative processes could guide treatment monitoring and prognosis.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled